BMS' head and neck cancer hopes take a hit with Opdivo-Yervoy trial flop

fiercepharma | April 25, 2019

BMS' head and neck cancer hopes take a hit with Opdivo-Yervoy trial flop
Bristol-Myers Squibb already has one Opdivo approval in previously treated head and neck cancer, but it won’t make that two. The company, which was testing its immuno-oncology star alongside Yervoy in previously treated patients whose disease had recurred or spread, said Thursday that the pair had failed to outdo Opdivo on its own. For now at least, Bristol isn’t sharing details on the phase 2 miss. But one thing is clear: The regimen won’t be backing up Opdivo in second-line head and neck cancer, where it’s currently battling Merck’s Keytruda.

Spotlight

Advancements in neurotechnology are blurring the line between biology and technology. There is an emerging push to implant electronic devices inside the human body, hardwire them to our brains, and allow us to not only overcome disadvantages or injury but open up entirely new avenues of human experience.

Related News

BUSINESS INSIGHTS

INNOTECH and OSARO Collaborate to Build a Demonstration AI Picking Robot System for Rohto Pharmaceutical’s Next-generation Smart Factory

INNOTECH and OSARO | January 12, 2022

OSARO Inc. a global leader in the development and provision of advanced robotics automation, and INNOTECH CORPORATION, which provides advanced products for electronics and consumer industries, have announced a collaboration to create an innovative demonstration for Rohto Pharmaceutical Co., Ltd. using AI piece-picking robots. The two companies are jointly providing picking robots and jointly building a system for their introduction into a new factory production line, scheduled for completion in 2022. OSARO will take the lead in providing AI software to improve the efficiency of robot operations, and INNOTECH will provide support from demonstration testing to integration of the AI software. By automating the picking of bottle products, one of the most labor-intensive tasks in the production process, with robots, the collaboration aims to reduce the workload and improve productivity at the Rohto factory. Rohto produces OTC medicines, beauty products and supplements. In the eye care category, sales of OTC eye drops account for more than 40 percent of the Japanese market. “We are honored to have OSARO's picking technology recognized by the next-generation smart factory of Rohto Pharmaceutical Co. We believe that the ability to integrate with existing equipment is a great advantage to create a new model case for Japan’s future factories and warehouses.” OSARO CEO Derik Pridmore Yosuke Kaburaki, Director, INNOTECH CORPORATION stated: “We have been conducting basic experiments with Rohto Pharmaceutical using robots that incorporate OSARO's AI software. In the future, INNOTECH will continue to speed up the integration of OSARO's software technology into Rohto's production process to make it more effective and efficient.” About INNOTECH CORPORATION Yokohama City, Kanagawa Prefecture, Japan INNOTECH provides comprehensive technology and support solutions for customer product development and manufacturing. Since 2000, INNOTECH has engaged in the business of internally developed products, leveraging its technical knowledge, strengthened by its existing and expanding business relationships. Today, INNOTECH continues to evolve as a total solution company, with hardware, software, consulting and support offerings for customers’ design, development, and mass production activities, leading up to the introduction of their final products. About OSARO, San Francisco, CA, USA OSARO designs and deploys robotics automation solutions in the materials handling industry using software-defined robotics. OSARO automation systems bring together advanced machine learning for object recognition with powerful control software that adapts to customer data and environments. The company’s robotic piece-picking solution is optimized for grocery, cosmetic, and e-commerce markets, where key challenges include high SKU inventories, complex packaging, and fragile items requiring delicate handling. OSARO Solutions have been validated by the world’s leading retailers, system integrators, and third-party logistic companies.

Read More

Grifols to acquire Montreal-based plasma fractionation facility and two purification facilities for US$460 million

Grifols, Green Cross Corporation | July 21, 2020

Grifols, a global healthcare company and one of world's top producers of plasma-derived medicines, today announced it has executed purchase arrangements with the South Korean-based GC Pharma (Group) whereby Grifols will acquire the Montreal-based plasma fractionation facility and two purification facilities, along with 11 U.S.-based plasma collection centers for a total amount of US$460 million. The transaction is part of Grifols' sustainable global growth strategy to expand plasma collection and fractionation capacity to ensure patients worldwide have safe and secure access to life-saving plasma-derived medicines. Most importantly, this strategic acquisition will strengthen Grifols' presence in Canada, building on a legacy of partnership in Canada's blood system. For more than three decades, Grifols has been a fractionator of Canadian plasma under contract manufacturing services, providing trusted plasma-derived medicines for Canadian patients and their healthcare providers. Throughout these many years Grifols has gained firsthand knowledge of the Canadian healthcare system. This transaction further demonstrates Grifols' commitment to supporting domestic self-sufficiency and security of plasma-protein-product supply.

Read More

RESEARCH

Pfizer, Moderna urge calm as they launch tests of vaccines against mutated COVID-19

Pfizer | December 29, 2020

After a changed, quick spreading variation of COVID-19 in the U.K. disturbed worldwide travel throughout the end of the week, an upsetting inquiry arose: Will the new antibodies from Pfizer and Moderna neutralize this startling new strain of the infection? Presently the two organizations, alongside Pfizer's COVID-19 accomplice BioNTech, are racing to quiet an apprehensive public. They're dispatching new investigations intended to demonstrate their mRNA-based shots will fight off the new Covid strain, while at the same time communicating certainty this new antibody innovation is ideal for ensuring against quickly changing infections. Pfizer and BioNTech have tried their antibody "for its capacity to kill various freak strains. Until now, we have discovered steady inclusion of the multitude of strains tried," they said in an assertion. The organizations are currently gathering information from individuals who have gotten the shot to decide how well they "might have the option to kill the new strain from the U.K.," Pfizer added. Moderna didn't promptly react to a solicitation for input yet said in an assertion gave to other news sources that it expects "that the Moderna immunization instigated insusceptibility would be defensive against the variations as of late portrayed in the U.K.," and that it "will play out extra tests in the coming a long time to affirm this desire." Pfizer brought up that when SARS-CoV-2, the infection that causes COVID-19, first arose a year prior, it was clear there was more than one strain of it, and that it was transforming as it spread. SARS-CoV-2 is a RNA infection, and all things considered, it has "astoundingly high [mutation] rates" on the grounds that the chemicals it utilizes for replication are "inclined to mistakes when making new infection duplicates," the organization said. "One reason Pfizer and BioNTech decided to use a mRNA stage is a direct result of the potential for the adaptability of the innovation in contrast with customary immunization advancements," including the capacity to change the RNA arrangement in the antibody, should a strain arise that is not covered by the current shot," Pfizer added.

Read More

Spotlight

Advancements in neurotechnology are blurring the line between biology and technology. There is an emerging push to implant electronic devices inside the human body, hardwire them to our brains, and allow us to not only overcome disadvantages or injury but open up entirely new avenues of human experience.